In several JIA sub-groups, treatment with TNF inhibition is recommended, particularly when conventional disease modifying antirheumatic drugs (cDMARDs) cannot achieve the defined target [114, 115]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.